Inolimomab

In today's world, Inolimomab is a topic that sparks great interest and debate. Whether due to its historical relevance, its impact on society or its influence on a personal level, Inolimomab is a topic that does not go unnoticed. Over the years, it has generated conflicting opinions and has been the subject of numerous studies and investigations. In this article, we will explore the different aspects related to Inolimomab, analyzing its importance, its implications and the various perspectives that exist around it. From its impact on popular culture to its relevance in the academic field, Inolimomab undoubtedly stands as a topic of great importance today.

Inolimomab
Monoclonal antibody
TypeWhole antibody
SourceMouse
TargetCD25
Clinical data
ATC code
  • none
Identifiers
CAS Number
ChemSpider
  • none
UNII
 ☒NcheckY (what is this?)  (verify)

Inolimomab is a mouse monoclonal antibody developed as an immunosuppressive drug against graft-versus-host disease. Its target is the alpha chain of the interleukin-2 receptor.[1][2]

References

  1. ^ Piñana JL, Valcárcel D, Martino R, Moreno ME, Sureda A, Briones J, et al. (November 2006). "Encouraging results with inolimomab (anti-IL-2 receptor) as treatment for refractory acute graft-versus-host disease". Biology of Blood and Marrow Transplantation. 12 (11): 1135–1141. doi:10.1016/j.bbmt.2006.06.010. PMID 17085306.
  2. ^ Dartois C, Freyer G, Michallet M, Hénin E, You B, Darlavoix I, et al. (2007). "Exposure-effect population model of inolimomab, a monoclonal antibody administered in first-line treatment for acute graft-versus-host disease". Clinical Pharmacokinetics. 46 (5): 417–432. doi:10.2165/00003088-200746050-00004. PMC 2760126. PMID 17465640.
Stub icon

This monoclonal antibody–related article is a stub. You can help Wikipedia by expanding it.

Stub icon

This antineoplastic or immunomodulatory drug article is a stub. You can help Wikipedia by expanding it.